Stereoselective anticonvulsant and pharmacokinetic analysis of valnoctamide, a CNS-active derivative of valproic acid with low teratogenic potential

Epilepsia

Volumn 55, Issue 2, 2014, Pages 353-361

  Shekh Ahmad, Tawfeeq ^a   Hen, Naama ^a   Yagen, Boris ^a,b   McDonough, John H ^c   Finnell, Richard H ^d   Wlodarczyk, Bogdan J ^d   Bialer, Meir ^a,b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c US ARMY MEDICAL RESEARCH INSTITUTE OF CHEMICAL DEFENSE   (United States)

^d UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Chiral switch; CNS drugs; New antiepileptic drugs; Strereoselective pharmacokinetic and pharmacodynamics analysis

Indexed keywords

CHIRAL SWITCH; CNS DRUGS; NEW ANTIEPILEPTIC DRUGS; STREREOSELECTIVE PHARMACOKINETIC AND PHARMACODYNAMICS ANALYSIS;

AMIDES; ANIMALS; ANTICONVULSANTS; CENTRAL NERVOUS SYSTEM STIMULANTS; MALE; MICE; NEURAL TUBE DEFECTS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; STATUS EPILEPTICUS; STEREOISOMERISM; TERATOGENS; VALPROIC ACID;

EID: 84894082208     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.12480     Document Type: Article

References (38)

1. Barel S, Yagen B, Schurig V, et al. Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and in patients with epilepsy. Clin Pharmacol Ther 1997; 61: 442-449.
2. Bialer M, Yagen B,. Valproic acid-second generation. Neurotherapeutics 2007; 4: 130-137.
3. Bialer M,. Chemical properties of antiepileptic drugs (AEDs). Adv Drug Deliv Rev 2012; 64: 887-895.
4. Bialer M, Haj-Yehia A, Barzaghi N, et al. Pharmacokinetics of a valpromide isomer, valnoctamide, in healthy subjects. Eur J Clin Pharmacol 1990; 38: 289-291.
5. Bialer M,. Clinical pharmacology of valpromide. Clin Pharmacokinet 1991; 20: 114-122.
6. Bialer M, White HS,. Key factors in the discovery and development of new antiepileptic drugs (AEDs). Nat Rev Drug Discov 2010; 9: 68-83.
7. Melissant CF, Vinks AATM, Sleeboom HP,. Coma due to overdose of valnoctamide. Ned Tijdschr Geneeskd [Dutch Med J] 1992; 132: 793-794.
8. Stepansky W,. A clinical study in the use of valmethamide, an anxiety-reducing drug. Curr Ther Res 1960; 2: 144-147.
9. White HS, Alex AB, Pollock A, et al. A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage. Epilepsia 2012; 53: 134-146.
10. Pouliot W, Bialer M, Hen N, et al. Electrographic analysis of the effect of sec-butyl-propylacetamide on pharmacoresistant status epilepticus. Neuroscience 2013; 231: 145-156.
11. Kaufmann D, Yagen B, Minert A, et al. Evaluation of the antiallodynic, teratogenic and pharmacokinetic profile of stereoisomers of valnoctamide, an amide derivative of a chiral isomer of valproic acid. Neuropharmacology 2010; 52: 1228-1236.
12. Finnell RH, Bennett GD, Karras SB, et al. Common hierarchies of susceptibility to the induction of neural tube defects in mouse embryos by valproic acid and its 4-propyl-4-pentenoic acid metabolite. Teratology 1988; 38: 313-320.
13. Shalitiel G, Mark S, Kofman O, et al. Effect of valproate derivatives on human brain-myo-inositol-1-phosphate (MIP) synthase activity and amphetamine-induced rearing. Pharmacol Rep 2007; 59: 402-407.
14. Bersudsky Y, Applebaum J, Gaiduk Y, et al. Valnoctamide as valproate substitute with low teratogenic potential in mania: double blind controlled clinical trial. Bipolar Disord 2010; 12: 376-382.
15. Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res 2010; 92: 89-124.
16. Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI). Epilepsy Res 2013; 103: 2-30.
17. Agranat I, Caner H, Caldwell J,. Putting chirality to work: the strategy of chiral switches. Nat Rev Drug Discov 2002; 1: 753-768.
18. Tucker GT,. Chiral switches. Lancet 2003; 55: 1085-1087.
19. Bliss C,. The statistics of bioassay with special reference to the vitamins. In, Gyorgy P, (Ed.) Vitamin methods. New York: Academic Press, 1952: 445-628.
20. McDonough JH, Shih TM,. Pharmacological modulation of soman-induced seizures. Neurosci Biobehav Rev 1991; 17: 203-215.
21. Shih TM, McDonough JH,. Neurochemical mechanisms in soman-induced seizures. J Appl Toxicol 1991; 17: 255-264.
22. Finnell RH, Bielec B, Nau H,. Anticonvulsant drugs: mechanisms and pathogenesis of teratogenicity. In, Kavlock R, Daston G, (Eds.) Handbook of experimental pharmacology 124 (drug toxicity in embryonic development II). Berlin: Springer-Verlag, 1997: 121-159.
23. Finney DJ,. Statistical logic in the monitoring of reactions to therapeutic drugs. Methods Inf Med 1971; 10: 237-245.
24. Hen N, Shekh-Ahmad T, Yagen B, et al. Stereoselective pharmacoydnamic and pharmacokinetic analysis of sec-propyl-butylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. J Med Chem 2013; 56: 6467-6477.
25. Shekh-Ahmad T, Hen N, Yagen B, et al. Valnoctamide and sec-propyl-butylacetamide (SPD) for acute seizures and status epielpticus. Epilepsia 2013; 54 (Suppl. 5): 98-101.
26. Nalivaeva NN, Belyaev NCD, Turner AJ,. Sodium valproate: an old drugs with new roles. Trends Pharmacol Sci 2009; 30: 509-514.
27. Bialer M,. Why are antiepileptic drugs used for nonepileptic conditions? Epilepsia 2012; 50 (Suppl. 7): 26-33.
28. Jones DM, Esmaeil N, Maren S, et al. Characterization of pharmacoresistance to benzodiazepines in the rat Li-pilocarpine model of status epilepticus. Epilepsy Res 2002; 50: 301-312.
29. Haj-Yehia A, Bialer M,. Pharmacokinetics of a valpromide isomer, valnoctamide, in dogs. J Pharm Sci 1988; 77: 831-834.
30. Blotnik S, Bergman F, Bialer M,. The disposition of valpromide, valproic acid and valnoctamide in brain, liver, plasma and urine of rats. Drug Metab Dispos 1996; 24: 560-564.
31. Altman PL, Dittmer DS,. Biology data book. 2nd Ed., Vol. 3. Bethesda, MD: Federation of American Societies for Experimental Biology; 1974: 1702-1710.
32. Spiegelman O, Yagen B, Bennett GD, et al. Strereoselective pharmacokinetics of valnoctamide, a CNS-active chiral amide analogue of valproic acid in dogs, rats and mice. Ther Drug Monit 2000; 22: 574-581.
33. Meador KJ,. Effect of in-utero antiepileptic drug exposure. Epilepsy Curr 2009; 8: 144-147.
34. Spiegelman O, Yagen B, Levy RH, et al. Strereoselective pharmacokinetics and pharmacodynamics of propylisopropyl acetamide-a CNS-active chiral amide derivative of valproic acid. Pharm Res 1999; 16: 1582-1588.
35. FDA-Federal Register. Content and format of labeling for human prescription drug and biological products: requirements for pregnancy and lactation labeling. Fed Regist 2008; 73: 30381-30837.
36. Levy RH, Boddy AV,. Stereoselectivity in pharmacokinetics: a general theory. Pharm Res 1991; 8: 551-555.
37. Hubbard WK,. FDA policy on period of marketing exclusivity for newly approved drug products with enantiomer active ingredients; request for comments. Fed Regist 1997; 62: 2167-2169.
38. 50 values of antiepileptic drugs in mice and rats and their therapeutic doses and plasma levels. Epilepsy Behav 2004; 5: 866-872.